Oncorus Signs an Exclusive License Agreement with Gaeta for IL-12 in Combination with Immune Checkpoint Inhibitors to Treat Cancer

Shots:

• Gaeta to receive $0.2M up front and is eligible to receive ~$7.5M in clinical and regulatory milestones based on product and indication
• The agreement will expand Oncorus’ clinical development of ONCR-177 for the treatment of cancer patients in combination with pembrolizumab and other immunotherapies, and also helps to bolster the commercialization strategy of the product
• Oncorus is currently enrolling the patients in a P-I clinical trial of ONCR-177 as monothx. and in combination with Merck’s Keytruda for advanced & refractory solid tumors or with liver metastases. The results will be presented at SITC 2021

Click here to­ read the full press release/ article | Ref: Globe Newswire | Image: Oncorus